AURA Stock Overview
A clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Aura Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.33 |
| 52 Week High | US$12.38 |
| 52 Week Low | US$6.63 |
| Beta | 0.33 |
| 11 Month Change | 10.72% |
| 3 Month Change | 26.28% |
| 1 Year Change | 27.69% |
| 33 Year Change | -56.94% |
| 5 Year Change | n/a |
| Change since IPO | -30.20% |
Recent News & Updates
Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
Sep 17We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely
Sep 11
Recent updates
Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
Sep 17We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely
Sep 11We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Oct 03Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
Mar 28We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Oct 01Aura gains as JMP starts with Bullish view citing treatment platform
Jul 19Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer
Jun 30Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
Apr 10Shareholder Returns
| AURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.1% | -1.3% | 3.9% |
| 1Y | 27.7% | 22.8% | 33.2% |
Return vs Industry: AURA exceeded the US Biotechs industry which returned 22.8% over the past year.
Return vs Market: AURA underperformed the US Market which returned 33.2% over the past year.
Price Volatility
| AURA volatility | |
|---|---|
| AURA Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AURA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AURA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 89 | Eli de los Pinos | www.aurabiosciences.com |
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.
Aura Biosciences, Inc. Fundamentals Summary
| AURA fundamental statistics | |
|---|---|
| Market cap | US$528.31m |
| Earnings (TTM) | -US$83.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.2x
P/E RatioIs AURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AURA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$83.22m |
| Earnings | -US$83.22m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AURA perform over the long term?
See historical performance and comparison